Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a cultivate(MD) portfolio company reported financial results for the third quarter ended September 30, 2025.
Third Quarter & Recent Business Highlights
- Generated revenue of $11.8 million in the third quarter, a 58% increase over the same quarter last year
- Sold 1,584 total implant systems, a 53% increase over the prior year quarter
- Achieved gross margin of 76.2% for the third quarter
- Expanded I-Series humeral stem product line with the full commercial launch of the InSet™ 70
- Received FDA 510(k) clearance expanding I-Series humeral stem product line to include certain fracture indications
“We are very excited about our accelerating momentum through 2025, with first-half year-over-year revenue growth of 37% expanding to 58% in the third quarter, enabling us to increase our full-year revenue guidance,” said Rob Ball, CEO of Shoulder Innovations. “We continue to add new surgeon customers and drive rapid adoption of our advanced implant systems, while maintaining our focus on delivering additional innovations to market.”
